Genetic Association Of Bcl2 (rs2279115) Gene Polymorphism With Susceptibility To Oral Cancer - A Case Control Study In South Indian Population
Mithra.S1*, Vijayashree Priyadharshini2, Pratibha Ramani3
1 Department of Oral and Maxillofacial Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India.
2 Assistant Professor, BRULAC-DRC, Saveetha Dental College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India.
3 Professor & Head, Department of Oral and Maxillofacial Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India.
*Corresponding Author
Dr. Mithra.S,
Department of Oral and Maxillofacial Pathology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University,
Chennai, India.
E-mail: mithraswornappan@gmail.com
Received: April 20, 2021; Accepted: July 09, 2021; Published: July 20, 2021
Citation: Mithra.S, Vijayashree Priyadharshini, Pratibha Ramani. Genetic Association Of Bcl2 (rs2279115) Gene Polymorphism With Susceptibility To Oral Cancer – A Case Control Study In South Indian Population. Int J Dentistry Oral Sci. 2021;8(7):3431-3434.doi: dx.doi.org/10.19070/2377-8075-21000698
Copyright: Mithra.S©2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: Oral cancer is now one of the most serious health issues faced by mankind. The anti-apoptotic protein Bcl2 is one
of the most common anti-apoptotic proteins found in OSCC. They play a role in the growth of cancer and mediate resistance to
existing anticancer therapies.
Aim: To investigate the genetic association of Bcl2(rs2279115) gene polymorphism with susceptibility to oral cancer – a case control
study in the south Indian population.
Materials & Methods: About 5 ml of venous blood was collected from OSCC patients (n = 21) and controls (n = 25). DNA
extraction was performed using a buffy coat obtained from EDTA anti-coagulated blood following the protocol by Miller et al
(1988) salting out method. Genotyping was performed by PCR-RFLP method.
Results: The genotype and allele frequency for the polymorphism studied was almost similar in both case and control groups
returning an insignificant p value between the two groups. The major limitation of the study is the small sample size.
Conclusion: Bcl2 (rs2279115) gene polymorphisms could be a potential genetic marker as confirmed from other studies across
different populations. Recruiting more patients from different ethnic groups could indeed provide clues on the possible association
of Bcl2 polymorphism with OSCC.
2.Introduction
6.Conclusion
8.References
Keywords
Bcl-2; Carcinogenesis; Oral Cancer.
Introduction
Oral cancer is the most prevalent neoplasm of head and neck,
with 95% being oral squamous cell carcinoma globally [1]. The
prevalence of all oral cancers has escalated in past few decades.
Of all the cancers of head and neck, oral cancer is known to
have poor prognosis and mortality despite the advancements in
the treatment modalities [2, 3]. The development of oral cancer is
a multistep process in which malignant changes evolve over time
as a result of the accumulation of numerous genetic mutations
within cells. Hyperplastic disorders, dysplastic cellular appearance,
unorganised deregulated cell formation, and eventually carcinoma
are all caused by these genetic mutations [3, 4]. The oral cancers,
especially oral squamous cell carcinoma decreases the survival
rate at later stages of malignancy. So, early diagnosis of cancers
is important for determining the prognosis and recurrence. The
detection of abnormal gene expressions and changes at the molecular
level would greatly aid in the early diagnosis of oral cancer.
The significant proportion of cancers is caused by a deviation in
the direction of programmed cell death (apoptosis), which can result
in tumour pathogenesis and progression. B-cell lymphoma/
leukemia-2 (Bcl2) is an anti-apoptotic protein which is a part of
the regulatory system that controls the cell cycle and the induction
of apoptosis. The core of the apoptotic programme and the main
effectors arm of the cell death programme are the Bcl-2 gene family
and related proteins. Unlike most other oncogenes that facilitate
cell cycle progression, the bcl-2 oncogenes was discovered to protect cells from undergoing apoptosis in response to a variety
of stimuli [4].
Previous literature have identified genetic alterations in Bcl-2 leading
to different carcinomas. Muzio et al, found that it is possible
to suggest bcl-2 as an early marker of prognosis in oral squamous
cell carcinoma [7]. Sulkowska et al, hypothesised potential links
between Bcl-2 protein expression and OSCC clinic pathological
features [8]. They have particularly evaluated OSCC rather than
all oral cancers in Indian population. The aim of this research is
to identify the Genetic alteration in bcl2 family of genes and their
putative association with oral cancers in south Indian population.
Material And Methods
Sample selection
All the samples for the current study are selected based on the
WHO/ISH guidelines. Clinical investigations were carried out by
qualified physicians and informed consent was obtained from all
the patients and controls. About 5ml of blood sample was collected
from oral cancer patients (n=21) and control (n=25) between
the age group of 20 and 65 years. Patients’ samples were collected
from Saveetha Dental College and Hospitals, Saveetha University
(SIMATS). Patients with other systematic diseases were excluded
from the study. The study was approved by the Institutional Human
Ethical Committee.
Genotyping
Genomic DNA was extracted from the buffy coat of EDTA
anti-coagulated blood using the Miller et al. (1988) salting out
method [9]. Genotype analysis for the SNP marker was based
on PCR-RFLP method. PCR was performed in 20 µl volumes
using 100 ng of genomic DNA as template, using primers,
BCL2-F: 5’-GCGCTCGGCACCGGCGG-3’ and BCL2-R:
5’-GGCAGCGGCGGCGGCAG-3’ (Eurofins MWG Operon,
Bangalore, India). The segment of Bcl2 gene spanning the polymorphism
was amplified following PCR conditions, which involved
an initial denaturation at 94°C for 5 min, denaturation at
94°C for 35 sec, annealing at 55°C for 35 sec, extension at 72°C
for 35 sec, and a final extension at 72°C for 5 min. About 5 µl
of PCR product was checked on a 1.5% agarose gel (Fig. 1A). 15
µl of PCR product was digested using BccI restriction enzyme
procured from New England Biolabs, England. Digestion was
carried out at 37°C for 2 h. The digested product was visualized
on a 2% agarose gel and the results were documented (Fig. 1B).
Comparison of allele frequencies between different ethnic groups
was performed from the data obtained from Ensembl genome
browser [10].
Statistical analysis
The mean and standard deviation of continuous variables were
calculated. The Student's t-test was used to compare the means of
various variables. The Chi-square test was used to see whether the
genotype distribution deviated from Hardy–Weinberg equilibrium
and whether there were any major variations in allele or genotype
frequencies between the cases and controls. The relationship between
genotypes and oral cancer was investigated using the odds
ratio (OR) with a 95% confidence interval (95 percent CI). The
statistical package SPSS 14.0 version (SPSS Inc., Chicago, Illinois,
USA) was used to conduct statistical tests, including logistic regression
analysis. Statistical significance was described as a p value
of less than 0.05.
Results
High molecular weight genomic DNA was isolated from the patients
and control subjects (Figure 1). In vitro amplification of
the gene of interest spanning the polymorphic site in the Bcl2
gene was performed under controlled conditions, which yielded
amplicon of size 300 bp (Figure 2). Genotyping was performed
using the RFLP approach. The enzyme used for the purpose was
BccI, which cleaves the amplicon into 2 fragments of size 137 bp
and 163 bp corresponding to the presence of A allele. An uncut
300 bp product corresponds to C allele and the combination of
both alleles (CA genotype) presents with 3 bands upon digestion
with BccI (Figure 3). The genotype and allele frequency for the
rs2279115 of Bcl2 gene was found to be similar between the case
(C=71% and A=29%) and the control (C=72% and A=28%)
groups. The genotype frequency of cases and controls did not
differ significantly at two degrees of freedom returning a p value
of 0.955, where 0.05 was considered to be statistically significant.
Upon segregation of genotypes based on different models viz.,
dominant, recessive and additive, the p value remained insignificant
in the present study group. The possible reason for such an
observation could be attributed to small sample size. Increasing
the sample size could aid in deriving possible association between
the gene polymorphism and OSCC. A comparison of allele frequencies
among different populations for the Bcl2 polymorphism
showed that the allele frequency observed in the present study
was similar to that observed in the south Asian population as
identified from the database.
Figure 2. (A) Agarose gel electrophoretogram of BCL2 rs2279115 C/A polymorphism spanning region of size 300 bp (Lanes 1-3: Amplified product; M: 100 bp DNA ladder). (B) BccI digestion of PCR amplified product (Lanes 1, 2, 4, 5: Homozygous AA, Lanes 6-11: Heterozygous AC, Lane 3: Homozygous CC).
Figure 3. Comparison of allele frequencies of gene polymorphism among different populations with the present study group*.
Table 2. Genotype distribution of the Bcl2 rs2279115 gene polymorphism in cases and controls based on different models.
Discussion
Oral cancers are characterized by a combination of molecular
events that increase the risk of the interaction of a person's genetic
predisposition and exposure to carcinogens in the environment
[11]. Tobacco, alcohol, oncogenes, viruses, and inflammation
are all carcinogens that can alter individual genes as well as larger portions of the genetic material, including chromosomes.
Multiple chromosomes and genes are affected by subsequent genetic
damage, and the accumulation of these modifications tends
to lead to carcinoma in certain cases, often via a clinically visible
pre-malignant or potentially malignant lesion [12]. Activating
mutations or amplification of oncogenes that encourage cell
survival and proliferation, as well as inactivation of tumor suppressor
genes that inhibit cell proliferation, are among the genetic
changes [14]. While lifestyle factors play a significant role in aetiology,
some patients tend to be predisposed due to an inherited
trait that affects their ability or inability to metabolise carcinogens
or pro-carcinogens, likely in combination with a reduced ability to
repair DNA damage [12, 13].
Programmed cell death is called apoptosis which is a normal
physiological process; but abnormal levels of apoptosis are potentially
dangerous. Defects in apoptosis are predominating in
multiple disorders, especially carcinomas [15]. The Bcl-2 protein
family either promotes cell survival, initiates cell death, triggers
the effector pathways of apoptosis or activate the effector path-ways of apoptosis [16]. High levels of Bcl-2 expression have been
identified in a variety of solid tumours, not just haematological
malignancies. Cingeetham et al, revealed that Bcl2 genotypes were
significantly associated with increased risk for acute myeloid leukemia
occurrence [19].
Also in recent decades the incidences of oral cancer have increased
to a greater extent. Few researches have also attempted to
estimate the correlation between Bcl2 mutations/polymorphisms
in oral cancers. Dorjgochoo et al, observed associations between
genetic variants in the Bcl2 gene and endometrial cancer risk. In
human endometrial carcinoma tissues, BCL2 expression may be
a sign of apoptosis inhibition [20]. Suri et al. performed immunohistochemistry
to test the expression, as well as quantify and
assess the strength and pattern of Bcl-2 in various histological
grades of OSCC. From well-differentiated to poorly differentiated
OSCCs, the number of cells expressing Bcl-2 increased, showing
an inverse association with differentiation [21]. Loro et al. used
immunohistochemistry to identify the loss of Bcl2 in oral epithelial
dysplasia and OSCC, which could be due to bcl-2 mutations.
No mutations were discovered that could explain the loss of bcl2
in oral dysplasia and carcinoma [22]. Since the expression of the
Bcl-2 oncogene is required for tumour development, Gibson et al.
investigated the effect of anti-Bcl-2 ribozyme on the phenotype
of oral cancer cells and discovered that anti-Bcl-2 activity was
successful in the treatment of oral cancer [23]. Fernández-Mateos
et al,found a significant correlation between Bcl2 gene and oral
cavity cancer susceptibility. They also identified that the presence
of C allele highly reduces the activity of P1 and Bcl-2 protein
expression; increasing apoptosis which indicates Bcl2 (rs2279115)
polymorphism found in P2 gene promoter, acting as a negative
regulator element, decreasing P1 promoter activity [17, 18].
The current research indicates that Bcl2 rs2279115 C/A polymorphism
acts as an independent risk factor for oral cancer. Although
we did not observe any significant change between the two groups
in the present study, the study can be extended to a large number
of samples of different grades and from different populations.
Since the distribution of Bcl2 (rs2279115) gene polymorphisms
were in concordance with the Hardy–Weinberg equilibrium, the
results of this study are unlikely to be biased. The major limitation
of the study is considered to be the sample size.
Conclusion
The present study demonstrates the possible association of Bcl2
gene polymorphism with oral cancer. Although not significant,
other variants in Bcl2 gene can be investigated further to identify
potential drivers of Bcl2 gene in relation to oral cancer.
References
- Ayaz B, Saleem KH, Azim WA, Shaikh AL. A clinico-pathological study of oral cancers. Biomedica. 2011 Jan;27(1):29-32.
- Juliana Noguti, Carolina Foot Gomes De Moura, Gustavo Protasio Pacheco De Jesus, Victor Hugo Pereira Da Silva, Thais AyakoHossaka, Celina Tijuko Fujiyama Oshima, et al. Cancer Genomics & Proteomics.2012 Sep 9; (5) 329-335.
- Jaikumarr Ram A, Girija As S, Jayaseelan VP, Arumugam P. Overexpression of BASP1 Indicates a Poor Prognosis in Head and Neck Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2020 Nov 1;21(11):3435-3439. PubmedPMID: 33247706.
- Aparna J, Smiline-Girija AS, Paramasivam A, Vijayashree-Priyadharsini J. Deciphering the genetic alterations in matrix metallo-proteinase gene family and its putative association with head and neck squamous cell carcinoma. MolBiol Res Commun. 2021 Mar;10(1):13-22. PubmedPMID: 33681393.
- Tanaka T, Ishigamori R. Understanding carcinogenesis for fighting oral cancer. J Oncol. 2011;2011:603740. Pubmed PMID: 21772845.
- Arumugam J, Jeddy N, Ramamurthy A, Thangavelu R. The expression of Bcl-2 in oral squamous cell carcinoma-A review. Journal of Orofacial Sciences. 2017 Jul 1;9(2):71.
- Lo Muzio L, Falaschini S, Farina A, Rubini C, Pezzetti F, Campisi G, et al. Bcl-2 as prognostic factor in head and neck squamous cell carcinoma. Oncol Res. 2005;15(5):249-55. PubmedPMID: 16261844.
- Sulkowska M, Famulski W, Sulkowski S, Reszec J, Koda M, Baltaziak M, et al. Correlation between Bcl-2 protein expression and some clinicopathological features of oral squamous cell carcinoma. Pol J Pathol. 2003 Jan 1;54(1):49-52.
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215. PubmedPMID: 3344216.
- Hunt SE, McLaren W, Gil L, Thormann A, Schuilenburg H, Sheppard D, et al. Ensembl variation resources. Database (Oxford). 2018 Jan 1;2018:bay119. PubmedPMID: 30576484.
- Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996 Jun 1;56(11):2488-92. PubmedPMID: 8653682.
- Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 2000 May;36(3):256-63. PubmedPMID: 10793327.
- Jain A, Selvi SG, Arumugam P, Jayaseelan VP. A Computational Approach to Identify the Mutations in the Genes of the RTK Signaling Pathway and their Possible Association with Oral Squamous Cell Carcinoma. Middle East Journal of Cancer. 2021 Jan 1;12(1):1-9.
- Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008 Jan;87(1):14-32. PubmedPMID: 18096889.
- Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med. 2009 Oct 15;361(16):1570-83. PubmedPMID: 19828534.
- Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011 Sep;18(9):1414- 24. PubmedPMID: 21415859.
- Fernández-Mateos J, Seijas-Tamayo R, AdansaKlain JC, Pastor Borgoñón M, Pérez-Ruiz E, Mesía R, et al. Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population. Cancers (Basel). 2019 Apr 7;11(4):493. PubmedPMID: 30959967.
- Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nückel H, et al. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol. 2009 Jun;20(6):1094-9. PubmedPMID: 19196738.
- Cingeetham A, Vuree S, Dunna NR, Gorre M, Nanchari SR, Edathara PM, et al. Influence of BCL2-938C>A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India. Tumour Biol. 2015 Sep;36(10):7967-76. PubmedPMID: 25957891.
- Dorjgochoo T, Xiang YB, Long J, Shi J, Deming S, Xu WH, et al. Association of genetic markers in the BCL-2 family of apoptosis-related genes with endometrial cancer risk in a Chinese population. PLoS One. 2013 Apr 23;8(4):e60915. PubmedPMID: 23637776.
- Suri C. The immunohistochemical evaluation of the expression of BCL-2 in different histological grades of squamous cell carcinoma. J ClinDiagn Res. 2009;3(6):1891-99.
- Loro LL, Johannessen AC, Vintermyr OK. Loss of BCL-2 in the progression of oral cancer is not attributable to mutations. J ClinPathol. 2005 Nov;58(11):1157-62. PubmedPMID: 16254104.
- Gibson SA, Pellenz C, Hutchison RE, Davey FR, Shillitoe EJ. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res. 2000 Jan;6(1):213-22. PubmedPMID: 10656452.